JCCG 活動情報 －論文投稿 2022 年―
（主）
：主論文

神経芽腫委員会
Hara J, Nitani C, Shichino H, Kuroda T, Hishiki T, Soejima T, Mori T, Matsumoto K, Sasahara Y, IeharaT, Miyamura T, Kosaka Y, Takimoto T, Nakagawara A, Tajiri T, JNBSG. Outcome of children with relapsed
high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem celltransplantation. Jpn J Clin Oncol. 52:486. 2022. PMID:35137156

肝腫瘍委員会（主）Watanabe K, Mori M, Hishiki T, Yokoi A, Ida K, Yano M, Fujimura J, Nogami Y, Iehara T, Hoshino
K, Inoue T, Tanaka Y, Miyazaki O, Takimoto T, Yoshimura K, Hiyama E. Feasibility of dose-dense
cisplatin-based chemotherapy in Japanese children with high-risk hepatoblastoma: Analysis of the JPLT3H pilot study. Pediatr Blood Cancer. 69:e29389. 2022. PMID:34606680.
Kondo T, Honda S, Suzuki H, Ito YM, Kawakita I, Okumura K, Ara M, Minato M, Kitagawa N, Tanaka Y,Tanaka M, Shinkai M, Hishiki T, Watanabe K, Ida K, Takatori A, Hiyama E, Taketomi A. A novel risk
stratification model based on the Children's Hepatic Tumours International Collaboration-Hepatoblastoma
Stratification and deoxyribonucleic acid methylation analysis for hepatoblastoma. Eur J Cancer. 172:311.
2022. PMID:35816972.
Hiyama Y, Yamaoka E, Fukazawa T, Kojima M, Sotomaru Y, Hiyama E. In Vitro Transfection of UpRegulated Genes Identified in Favorable-Outcome Neuroblastoma into Cell Lines. Cells. 2022 Oct
10;11(19):3171. doi:10.3390/cells11193171.
Hishiki T, Honda S, Takama Y, Inomata Y, Okajima H, Hoshino K, Suzuki T, Souzaki R, Wada M, Kasahara
M, Mizuta K, Oue T, Yokoi A, Kazama T, Komatsu S, Saeki I, Miyazaki O, Takimoto T, Ida K, Watanabe
K, Hiyama E. Feasibility of Real-Time Central Surgical Review for Patients with Advanced-Stage
Hepatoblastoma in the JPLT3 Trial. Children (Basel). 9:234. 2022. PMID:35204954

リンパ腫委員会
Emma Kroeze, Laura Arias Padilla, Max Bakker, Judith M Boer, Melanie M Hagleitner, Birgit Burkhardt,

Takeshi Mori, Andishe Attarbaschi, Jaime Verdú-Amorós, Marta Pillon, Liliya Anderzhanova, EditaKabíčková, Alan K S Chiang, Rejin Kebudi, Karin Mellgren, Jelena Lazic, Janez Jazbec, Jules P P Meijerink,Auke Beishuizen, Jan L C Loeffen; European Intergroup for Childhood Non-Hodgkin Lymphoma(EICNHL) and the International Berlin–Frankfurt–Münster (i-BFM) Study. Pediatric Precursor B-Cell
Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement. Cancers (Basel). 14:3895.
2022. PMID:36010889

AML 委員会
Bertrums EJM, Zwaan CM, Hasegawa D, De Haas V, Reinhardt DN, Locatelli F, De Moerloose B, Dworzak
M, Buijs A, Smisek P, Kolenova A, Pronk CJ, Klusmann JH, Carboné A, Ferster A, Antoniou E, Meshinchi
S, Raimondi SC, Niemeyer CM, Hasle H, Van den Heuvel-Eibrink MM, Goemans BF. Guideline formanagement of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM
AML Study Group and EWOG-MDS. Haematologica. 107:759. 2022. PMID:34854279
Kaburagi T, Yamato G, Shiba N, Yoshida K, Hara Y, Tabuchi K, Shiraishi Y, Ohki K, Sotomatsu M, Arakawa
H, Matsuo H, Shimada A, Taki T, Kiyokawa N, Tomizawa D, Horibe K, Miyano S, Taga T, Adachi S, Ogawa
S, Hayashi Y. Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.
Haematologica. 107:583. 2022. PMID:33730843
Yamato G, Kawai T, Shiba N, Ikeda J, Hara Y, Ohki K, Tsujimoto SI, Kaburagi T, Yoshida K, Shiraishi Y,Miyano S, Kiyokawa N, Tomizawa D, Shimada A, Sotomatsu M, Arakawa H, Adachi S, Taga T, Horibe K,Ogawa S, Hata K, Hayashi Y. Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia.
Blood Adv. 6:3207. 2022. PMID:35008106
Tomizawa D, Tsujimoto SI, Tanaka S, Matsubayashi J, Aoki T, Iwamoto S, Hasegawa D, Nagai K,Nakashima K, Kawaguchi K, Deguchi T, Kiyokawa N, Ohki K, Hiramatsu H, Shiba N, Terui K, Saito AM,Kato M, Taga T, Koshinaga T, Adachi S. A phase III clinical trial evaluating efficacy and safety of minimal
residual disease-based risk stratification for children with acute myeloid leukemia, incorporating arandomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for nonlow-risk patients (JPLSG-AML-20). Jpn J Clin Oncol. 52:1225. 2022. PMID:35809896

CML 腫委員会（主）Shima H, Kada A, Tanizawa A, Sato I, Tono C, Ito M, Yuza Y, Watanabe A, Kamibppu K, Uryu H,Koh K, Imai C, Yoshida N, Koga Y, Fujita N,Saito AM, Adachi S, Ishii E, Shimada H. Discontinuation oftyrosine kinase inhibitors in pediatric chronic myeloid leukemia. Pediatr Blood Cancer. 69:e29699. 2022.
PMID:35403816

再発 ALL 委員会
Tanaka K, Kato I, Dobashi Y, Imai JI, Mikami T, Kubota H, Ueno H, Ito M, Ogawa S, Nakahata T, Takita
J, Toyoda H, Ogawa C, Adachi S, Watanabe S, Goto H. The first Japanese biobank of patient-derived
pediatric acute lymphoblastic leukemia xenograft models. Cancer Sci. 113:3814. 2022. PMID:35879192

HLH/LCH 委員会
Ono R, Sakamoto K, Doi T, Yanagisawa R, Tamura A, Hashimoto H, Kanegane H, Ishii E, Nakazawa Y,Shioda Y; HLH/LCH committee members of the Japan Children’s Cancer Group. A retrospective surveyof patients who discontinued participation in the JPLSG HLH-2004 clinical trial. Int J Hematol. 116:434.
2022. PMID:35524025
Sakamoto K, Ono R, Doi T, Koga Y, Shioda Y; Japan HLH/LCH consortium. Reduced incidence ofhemophagocytic lymphohistiocytosis in Japan during the COVID-19 pandemic. Int J Hematol. 115:446.
2022. PMID:35113348
Kudo K, Toki T, Kanezaki R, Tanaka T, Kamio T, Sato T, Sasaki S, Imamura M, Imai C, Ando K, Kakuda
H, Doi T, Kawaguchi H, Irie M, Sasahara Y, Tamura A, Hasegawa D, Itakura Y, Watanabe K, Sakamoto K,Shioda Y, Kato M, Kudo K, Fukano R, Sato A, Yagasaki H, Kanegane H, Kato I, Umeda K, Adachi S, Kataoka
T, Kurose A, Nakazawa A, Terui K, Ito E. BRAF V600E-positive cells as molecular markers of bone marrowdisease in pediatric Langerhans cell histiocytosis. Haematologica. 107:1719. 2022. PMID:35295077
Shioda Y, Sakamoto K, Morimoto A. New biomarker paves the way for a clinical trial for neurodegenerationin Langerhans cell histiocytosis.. Br J Haematol. 198:623. 2022. PMID:35727899
Sakamoto K, Shioda Y. Radiologic zebra line sign in a patient with Langerhans cell histiocytosis onbisphosphonate therapy. EJHaem. 3:1046. 2022. PMID:36051035
Morimoto A, Shioda Y, Sakamoto K, Imamura T, Imashuku S, Japan LCH Study Group. Bone lesions ofLangerhans cell histiocytosis triggered by trauma in children. Pediatr Int. 64:e15199. 2022.
PMID:35770832

塩田曜子, 石井榮一. Langerhans 細胞組織球症以外の組織球症. 小児血液・腫瘍学. 2:526. 2022
森本 哲, 塩田曜子, 坂本謙一, 工藤 耕, 今村俊彦, 工藤寿子. ランゲルハンス細胞組織球症における病態解明と治療の展望. 臨床血液. 63:373. 2022
塩田曜子, 坂本謙一, 佐藤亜紀. ランゲルハンス細胞組織球症. 日本医師会雑誌. 151:282. 2022

ALL 委員会
Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M, Cario G, Cazzaniga G,
Escherich G, Harrison CJ, Heyman M, Hunger SP, Kiss C, Liu HC, Locatelli F, Loh ML, Manabe A, MannG, Pieters R, Pui CH, Rives S, Schmiegelow K, Silverman LB, Stary J, Vora A, Brown P. Remission,treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno
Consortium. Blood. 139:1785. 2022. PMID:34192312（主）Kodama Y, Sato A, Kato K, Sakaguchi H, Kato M, Kawasaki H, Hiramatsu H, Kato I, Taga T, Shimada
H. Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective surveyof the Japan Children's Cancer Group. Int J Hematol. 116:131. 2022. PMID:35349077
嶋田 博之. 小児フィラデルフィア染色体陽性急性リンパ性白血病の治療戦略. 臨床血液. 63:799. 2022.
Isobe T, Takagi M, Sato-Otsubo A, Nishimura A, Nagae G, Yamagishi C, Tamura M, Tanaka Y, Asada S,Takeda R, Tsuchiya A, Wang X, Yoshida K, Nannya Y, Ueno H, Akazawa R, Kato I, Mikami T, Watanabe
K, Sekiguchi M, Seki M, Kimura S, Hiwatari M, Kato M, Fukuda S, Tatsuno K, Tsutsumi S, Kanai A, Inaba
T, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Kotecha RS, Cruickshank MN, Ishikawa F, Morio T, Eguchi
M, Deguchi T, Kiyokawa N, Arakawa Y, Koh K, Aoki Y, Ishihara T, Tomizawa D, Miyamura T, Ishii E,Mizutani S, Wilson NK, Göttgens B, Miyano S, Kitamura T, Goyama S, Yokoyama A, Aburatani H, Ogawa
S, Takita J. Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acutelymphoblastic leukemia. Nat Commun. 13:4501. 2022. PMID:36042201
Arakawa Y, Hasegawa D, Miyamura T, Ohshima J, Kimura S, Imamura T, Koga Y, Yamamoto S, Ogawa A,Shinoda K, Eguchi M, Hosoi H, Imai K, Koh K, Tomizawa D. Postchemotherapy immune status in infants
with acute lymphoblastic leukemia: A report from the JPLSG MLL-10 trial. Pediatr Blood Cancer.
69:e29772. 2022. PMID:35796397

長期フォローアップ委員会（主）Masumoto D, Masumoto D, Nakagami-Yamaguchi E, Nambu M, Maeda M, Uryu H, Hayakawa A,Linn Z, Okamura S, Kurihara K, Kihira K, Deguchi T, Hori H. A pilot study of game-based learning
programs for childhood cancer survivors. BMC Cancer. 22:340. 2022. PMID:35351044（主）Soejima T, Nagayoshi M, Kibi S, Maeda M, Hayakawa A. Experiences of returning to school amongchildren with cancer and their families from the perspective of parents about providing information toschools.

TheJapanese

Journalof

Pediatric

Hematology/Oncology.

59:413.

2022.

doi:10.11412/jspho.59.413

支持療法委員会
佐野弘純，福島啓太郎，矢野道広，嘉数真理子，篠田邦大，加藤陽子，新小田雄一，森 尚子，石田裕二，
斎藤雄弥，豊田秀実，足立壯一，大曽根眞也. 本邦における小児白血病・リンパ腫診療時の中心静脈カテーテルの使用・管理法の現状. 日本小児血液・がん学会雑誌. 59:275. 2022.
新小田雄一，加藤陽子，森 尚子，大曽根眞也，嘉数真理子，佐野弘純，篠田邦大，矢野道広，石田裕二，
斎藤雄弥，澤田明久，豊田秀実，坂口公祥，足立壯一，福島啓太郎. 小児がん患者に対する検査・処置時の鎮静および疼痛管理の現状と課題―JCCG 施設調査より

第 3 報―. 日本小児血液・がん学会雑誌.

59:400. 2022.

名古屋データセンター
Nakamura K, Saito AM, Ueda K, Ueda K, Yoshihara K, Hiramatsu N, Yamashita Y, Kusaka Y, Ui H. Riskbased Approach to Determine the Need for an Audit:In What Situations Should an Audit Be Performed?.
Jpn J Pharmacol. 53:49. 2022

CML 委員会・長期フォローアップ委員会共同
Shima H, Kada A, Tanizawa A, Sato I, Tono C, Ito M, Yuza Y, Watanabe A, Kamibppu K, Uryu H, Koh K,Imai C, Yoshida N, Koga Y, Fujita N,Saito AM, Adachi S, Ishii E, Shimada H. Discontinuation of tyrosine
kinase inhibitors in pediatric chronic myeloid leukemia. Pediatr Blood Cancer. 69:e29699. 2022.
PMID:35403816